The ink was barely dry on the FDA approval letter for AstraZeneca’s Etcamah before the oral SERD suffered a key clinical ...
Following formal sign-off from the FDA, Handa Pharmaceuticals’ branded drug reformulation strategy has paid off for a third ...
In his first interview after taking the reins of the FDA’s Oncology Center of Excellence (OCE), Angelo de Claro, M.D., is ...
Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung ...
Takeda's long-time R&D chief Andy Plump will retire. Daiichi Sankyo beat back a $1.3 billion damage claim in a lawsuit.
With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...
Argonaut Manufacturing Services, a CDMO specializing in aseptic fill-finish for injectable biologics and other drugs, has ...
In a series of moves by Switzerland-headquartered CDMOs this week, manufacturing powerhouse Lonza is doubling down on its US ...
In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...
Caris Life Sciences is signing up Hollywood legend Kevin Costner to break down the importance of early cancer detection—and ...
Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board's oversight of ...
Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results